Solvonis Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	2020 - 2018
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	May '21 May 31, 2021	2020 - 2018
Net Income	-2.59	-1.59	-3.12	-2.71	-1.64	-0.45	Upgrade
Depreciation & Amortization	-0.06	-	0.18	0.11	0.08	0.11	Upgrade
Asset Writedown & Restructuring Costs	0.06	-	0.74	-	-	-	Upgrade
Stock-Based Compensation	0.5	0.32	0.37	0.86	-	-	Upgrade
Other Operating Activities	0.06	0.3	0.19	0.01	0.01	-0.07	Upgrade
Change in Accounts Receivable	0	0.03	0.01	0.04	-0.1	-0.03	Upgrade
Change in Inventory	-0.04	-	0.01	-0.19	-	-	Upgrade
Change in Accounts Payable	0.32	-0.06	0.39	-0.5	1.2	0.27	Upgrade
Operating Cash Flow	-1.72	-1.13	-1.24	-2.36	-0.44	-0.17	Upgrade
Capital Expenditures	-	-	-0.22	-0.72	-0	-0.02	Upgrade
Divestitures	-	-0.01	-	-	-	-	Upgrade
Other Investing Activities	-0.32	-0.32	-0.02	-	-	-	Upgrade
Investing Cash Flow	-0.31	-0.34	-0.23	-0.72	-0	-0.02	Upgrade
Short-Term Debt Issued	-	0.2	-	-	-	0.2	Upgrade
Total Debt Issued	-	0.2	-	-	0.51	0.2	Upgrade
Net Debt Issued (Repaid)	-	0.2	-	-	0.51	0.2	Upgrade
Issuance of Common Stock	3.81	1.92	-	4.48	0.86	-	Upgrade
Other Financing Activities	-0.07	-0.04	-	-0.34	-	-	Upgrade
Financing Cash Flow	3.74	2.08	-	4.14	1.37	0.2	Upgrade
Foreign Exchange Rate Adjustments	-0.02	-0.01	-0.02	-0.02	0.02	-0	Upgrade
Net Cash Flow	1.69	0.6	-1.49	1.04	0.96	0.01	Upgrade
Free Cash Flow	-1.72	-1.13	-1.45	-3.08	-0.44	-0.18	Upgrade
Free Cash Flow Margin	-	-	-247.70%	-567.90%	-116.44%	-34.81%	Upgrade
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.01	-0.00	Upgrade
Levered Free Cash Flow	0.09	-0.82	-0.8	-2.81	-	0.09	Upgrade
Unlevered Free Cash Flow	0.09	-0.78	-0.8	-2.81	-	0.09	Upgrade
Change in Working Capital	0.28	-0.03	0.41	-0.64	1.11	0.24	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.